Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ionis Pharmaceuticals

42.50
-0.2700-0.63%
Volume:835.93K
Turnover:35.69M
Market Cap:6.76B
PE:-14.18
High:43.30
Open:42.90
Low:42.29
Close:42.77
Loading ...

Press Release: Ionis to hold second quarter 2025 financial results webcast

Dow Jones
·
16 Jul

CEO Brett P. Monia Reports Disposal of Ionis Pharmaceuticals Inc. Common Shares

Reuters
·
16 Jul

Ionis Pharmaceuticals (IONS) Gets a Hold from Morgan Stanley

TIPRANKS
·
16 Jul

Ionis Pharmaceuticals Raised to Overweight From Equal-Weight by Barclays

Dow Jones
·
01 Jul

Ionis Pharmaceuticals Inc : Barclays Raises Target Price to $57 From $51

THOMSON REUTERS
·
01 Jul

Ionis Pharmaceuticals upgraded to Overweight from Equal Weight at Barclays

TIPRANKS
·
01 Jul

Ionis Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Jun

TD Cowen Reaffirms Their Buy Rating on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
26 Jun

Biogen to Advance SMA Treatment Into Registrational Studies

Dow Jones
·
25 Jun

Bernstein Remains a Hold on Ionis Pharmaceuticals (IONS)

TIPRANKS
·
20 Jun

Ionis Pharmaceuticals Is Maintained at Neutral by JP Morgan

Dow Jones
·
12 Jun

Ionis Pharmaceuticals Announces Retirement of Chief Development Officer Dr. Richard Geary; Dr. Holly Kordasiewicz to Succeed in January 2026

Reuters
·
12 Jun

Ionis Announces DR. Richard Geary, Chief Development Officer, to Retire; DR. Holly Kordasiewicz to Assume Role in January 2026

THOMSON REUTERS
·
12 Jun

Ionis Pharmaceuticals doses first patient in REVEAL study

TIPRANKS
·
11 Jun

Ionis Pharmaceuticals Inc - First Patient Dosed in Phase 3 Reveal Study of Ion582 for Angelman Syndrome

THOMSON REUTERS
·
11 Jun

Ionis Pharmaceuticals Initiates Phase 3 REVEAL Study of ION582 for Angelman Syndrome

Reuters
·
11 Jun

Ionis Pharmaceuticals Inc. Conducted Virtual Annual Stockholder Meeting

Reuters
·
10 Jun

Ionis Pharmaceuticals: Buy Rating Affirmed Amid Promising Clinical Trial Results and Future Prospects

TIPRANKS
·
21 May

Ionis Pharmaceuticals Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
20 May

Ionis Pharmaceuticals’ Promising Future: Buy Rating Backed by Positive Phase 3 Study Results and Upcoming Milestones

TIPRANKS
·
20 May